Rockwell Medical Reports Q4 & Full-Year 2025 Results: Achieves Adjusted EBITDA Profitability, Boosts Cash Position
RMTI is trading near its 52-week low of $0.78 (2.2% above the low).
Summary
Rockwell Medical announced Q4 and full-year 2025 financial results, highlighting Adjusted EBITDA profitability for the second consecutive year, a strong increase in cash position due to positive operating cash flow, and meeting its annual guidance.
Key Events · Earnings and Guidance · RMTI
-
Achieved Adjusted EBITDA Profitability
The company reported Adjusted EBITDA of $1.0 million for Q4 2025 and $0.3 million for full-year 2025, marking the second consecutive year of Adjusted EBITDA profitability and meeting its annual guidance.
-
Increased Cash Position
Cash and cash equivalents increased to $25.0 million at year-end 2025, up from $21.6 million at year-end 2024, driven by $2.3 million in positive cash flow from operating activities in Q4 2025.
-
Strong Q4 Gross Margin
Gross margin for Q4 2025 reached 21%, one of the strongest in company history and a meaningful improvement over 15% in Q4 2024, reflecting successful infrastructure adjustments.
-
Met 2025 Annual Guidance
Rockwell Medical's actual net sales, gross margin, and Adjusted EBITDA for 2025 were all in line with its annual guidance.
Analysis · RMTI · Life Sciences
Rockwell Medical, a company trading near its 52-week lows, reported a mixed but overall positive set of financial and operational results for Q4 and full-year 2025. While net sales declined year-over-year, the company achieved Adjusted EBITDA profitability for the second consecutive year and generated significant positive cash flow from operations in Q4 2025, substantially increasing its cash reserves. This focus on profitability and cash generation, coupled with meeting its 2025 guidance and providing positive 2026 guidance, is a critical signal of financial stabilization and operational execution for investors.
At the time of this filing, RMTI was trading at $0.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41M. The 52-week trading range was $0.78 to $2.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.